Maddie Pascoe

BSc Psychology

Assistant Research Fellow

New Zealand Brain Research Institute, Christchurch

This person is no longer at the institute and this page is for historical access to their publications only

Publications

Provided on request for non-commercial personal use by researchers.

2023

Download The New Zealand Parkinson’s Progression Programme.
MacAskill, M. R., Pitcher, T. L., Melzer, T. R., Myall, D. J., Horne, K.-L., Shoorangiz, R., Almuqbel, M. M., Livingston, L., Grenfell, S., Pascoe, M. J., Marshall, E. T., Marsh, S., Perry, S. E., Meissner, W. G., Theys, C., Le Heron, C. J., Keenan, R. J., Dalrymple-Alford, J. C., Anderson, T. J. (2023). The New Zealand Parkinson’s Progression Programme. Journal of the Royal Society of New Zealand, 53, 466-488. 10.1080/03036758.2022.2111448
Download Dimensions of apathy in Parkinson’s disease.
Thompson, N., MacAskill, M., Pascoe, M., Anderson, T., Heron, C. L. (2023). Dimensions of apathy in Parkinson’s disease. Brain and Behaviour, e2862, 1-8. 10.1002/brb3.2862

2021

Download Higher perceived stress and exacerbated motor symptoms in Parkinson's disease during the COVID-19 lockdown in New Zealand.
Blakemore, R. L., Pascoe, M. J., Horne, K. L., Livingston, L., Young, B. N., Elias, B., Goulden, M., Grenfell, S., Myall, D. J., Pitcher, T. L., Dalrymple-Alford, J. C., Le Heron, C. J., Anderson, T. J., MacAskill, M. R. (2021). Higher perceived stress and exacerbated motor symptoms in Parkinson's disease during the COVID-19 lockdown in New Zealand. The New Zealand Medical Journal, 134, 44-51.
Download Neuropsychiatric symptoms are associated with dementia in Parkinson’s disease but not predictive of it.
Horne, K., MacAskill, M. R., Myall, D. J., Livingston, L., Grenfell, S., Pascoe, M. J., Young, B., Shoorangiz, R., Melzer, T. R., Pitcher, T. L., Anderson, T. J., Dalrymple‐Alford, J. C. (2021). Neuropsychiatric symptoms are associated with dementia in Parkinson’s disease but not predictive of it. Movement Disorders Clinical Practice, 8, 390-399. 10.1002/mdc3.13151

2019

Download Beta amyloid deposition is not associated with cognitive impairment in Parkinson’s disease.
Melzer, T. R., Stark, M. R., Keenan, R. J., Myall, D. J., MacAskill, M. R., Pitcher, T. L., Livingston, L., Grenfell, S., Horne, K., Young, B., Pascoe, M., Almuqbel, M. A., Wang, J., Marsh, S., Miller, D. H., Dalrymple-Alford, J. C., Anderson, T. J. (2019). Beta amyloid deposition is not associated with cognitive impairment in Parkinson’s disease. Frontiers in Neurology, 10, 391. 10.3389/fneur.2019.00391
Download Altered grey matter volume, perfusion and white matter integrity in very low birthweight adults.
Pascoe, M.J., Melzer, T.R., Horwood, L.J., Woodward, L.J., Darlow, B.A. (2019). Altered grey matter volume, perfusion and white matter integrity in very low birthweight adults. NeuroImage: Clinical, 22, 101780. 10.1016/j.nicl.2019.101780

2018

Download The Symbol-Digit Modalities Test in mild cognitive impairment: evidence from Parkinson's disease patients.
Pascoe, M. J., Alamri, Y., Dalrymple-Alford, J. C., Anderson, T. J., MacAskill, M. R. (2018). The Symbol-Digit Modalities Test in mild cognitive impairment: evidence from Parkinson's disease patients. European Neurology, 79, 206-210. 10.1159/000485669

Abstracts and Short papers

2020

Download Neuropsychiatric symptoms are associated with dementia in Parkinson’s disease but not predictive of it.
Horne, K.-L., MacAskill, M. R., Myall, D., Livingston, L., Grenfell, S., Pascoe, M. J., Young, B., Shoorangiz, R., Melzer, T. R., Pitcher, T. L., Anderson, T. J., Dalrymple-Alford, J. C. (2020). Neuropsychiatric symptoms are associated with dementia in Parkinson’s disease but not predictive of it. MedRxiv, 2020, 09, 01, 20186312. https://doi.org/10.1101/2020.09.01.20186312

2019

Download Sensorimotor integration assessment by the Symbol-Digit modalities test in patients with Parkinson’s disease.
Alamri Y., Pascoe M. J., MacAskill M. R., Anderson T. J., Dalrymple-Alford J. C. (2019). Sensorimotor integration assessment by the Symbol-Digit modalities test in patients with Parkinson’s disease. Neurosciences 24, 143. 10.17712/nsj.2019.2.20190002